Denali Therapeutics Inc. (DNLI) stock

DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30

$18.89−0.84 (-4.26%)

Close on Nov 12, 2026Market cap $3.02BP/E –Yield –

Denali Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Denali Therapeutics's EV/EBITDA was 92.0× on Jan 31, 2022.

Period	Period end	Value	Change (pts)
2022	Jan 31, 2022	92.0×	−37.2
2021	Dec 31, 2021	129.2×	–

Parsed from the XBRL in Denali Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is DNLI.

Advertisement
300 × 250

See a number that looks wrong?